GH Research PLC (GHRS)

NASDAQ: GHRS · Real-Time Price · USD

18.61

+0.17 (0.92%)

Nov 6, 2026, 4:00 PM EST - Market closed

GH Research Earnings Call Transcripts

Fiscal Year 2025

Status Update
GH001 showed rapid, robust, and sustained efficacy in TRD, with a high remission rate and favorable safety profile. Long-term data indicate durable remission with infrequent treatments and fewer clinic visits compared to current standards.

Read full transcript →

Press release